Maze Therapeutics (MAZE) director Herve Hoppenot awarded 18,000 stock options at $23.58
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Maze Therapeutics director Herve Hoppenot received a grant of stock options to buy 18,000 shares of Common Stock at an exercise price of $23.58 per share. The options were granted on June 8, 2026 and will vest fully on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, contingent on his continued service. The options expire on June 7, 2036 and are held directly, representing equity-based, non-cash compensation rather than an open-market transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Hoppenot Herve
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 18,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 18,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 18,000 options
Exercise price: $23.58 per share
Underlying shares: 18,000 shares
+3 more
6 metrics
Option grant size
18,000 options
Stock Option (Right to Buy) granted June 8, 2026
Exercise price
$23.58 per share
Exercise price of option to buy Common Stock
Underlying shares
18,000 shares
Underlying Common Stock per option grant
Post-grant derivative holdings
18,000 options
Total derivative securities following transaction
Expiration date
June 7, 2036
Option expiration
Vesting deadline
June 8, 2027
Latest possible full vesting date, tied to service
Key Terms
Stock Option (Right to Buy), Common Stock, exercise price, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 23.5800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option shall vest and be fully exercisable on the earlier of..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-07T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did Maze Therapeutics (MAZE) director Herve Hoppenot report on this Form 4?
Herve Hoppenot reported receiving a grant of stock options for 18,000 shares of Maze Therapeutics Common Stock. These options are compensation-related and were not purchased in the open market, but awarded with a fixed exercise price and vesting schedule.
How many Maze Therapeutics (MAZE) options did Herve Hoppenot receive and at what price?
He was granted stock options covering 18,000 shares of Common Stock at an exercise price of $23.58 per share. This gives him the right, after vesting, to buy Maze shares at that fixed price until the options expire.
When do Herve Hoppenot’s Maze Therapeutics (MAZE) stock options vest?
The options vest and become fully exercisable on the earlier of Maze Therapeutics’ 2027 annual stockholders meeting or June 8, 2027. Vesting is conditioned on Hoppenot continuing to serve the company through the applicable vesting date.
When do the Maze Therapeutics (MAZE) stock options granted to Herve Hoppenot expire?
These stock options expire on June 7, 2036. After that date, any unexercised portion of the 18,000-share grant can no longer be exercised, so the long-dated term provides a substantial window for potential future exercise.
Is Herve Hoppenot’s Maze Therapeutics (MAZE) option grant an open-market buy or a compensation award?
The filing describes the transaction as a grant or award acquisition, coded “A,” indicating compensation-related options. No cash changed hands for an open-market purchase; instead, Hoppenot received options with a set exercise price and future vesting.
How many Maze Therapeutics (MAZE) derivative securities does Herve Hoppenot hold after this grant?
Following the reported transaction, he holds 18,000 stock options as indicated by the total shares following the transaction. This reflects the size of this specific option position reported in the filing for Maze Therapeutics.